This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 May;62(5):800-1.

doi: 10.1136/gutjnl-2012-304154. Epub 2012 Dec 11.

Secukinumab failure in Crohn's disease: the yeast connection?

Jean Frédéric Colombel, Boualem Sendid, Thierry Jouault, Daniel Poulain

PMID: 23232049
DOI: 10.1136/gutjnl-2012-304154

Comment

Secukinumab failure in Crohn's disease: the yeast connection?

Jean Frédéric Colombel et al. Gut. 2013 May.

. 2013 May;62(5):800-1.

doi: 10.1136/gutjnl-2012-304154. Epub 2012 Dec 11.

Authors

Jean Frédéric Colombel, Boualem Sendid, Thierry Jouault, Daniel Poulain

PMID: 23232049
DOI: 10.1136/gutjnl-2012-304154

No abstract available

PubMed Disclaimer

Comment on

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group. Hueber W, et al. Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17. Gut. 2012. PMID: 22595313 Free PMC article. Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information